본문 바로가기
KERD
논문KCI 등재

Coronavirus Disease 2019-Associated Pulmonary Aspergillosis

박완범|황영훈
대한의진균학회 (The Korean Society for Medical Mycology)|2022.03|대한의진균학회지 (Journal of Mycology and Infection)|제27권 제1호|pp. 1-8

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

COVID-19SARS-CoV-2Pulmonary aspergillosis
주제분류미생물학

초록

As the coronavirus disease 2019 (COVID-19) pandemic continues, a new disease, COVID-19-associated pulmonary aspergillosis (CAPA), is on the rise. CAPA is a secondary fungal infection in patients with critical COVID-19 receiving mechanical ventilation in intensive care units (ICUs). Although the incidence rate of CAPA is estimated to be 10.2% in ICU patients, CAPA appears to be associated with an increase in overall mortality. CAPA is like classical invasive pulmonary aspergillosis (IPA) but has an ambiguous clinical manifestation and occurs without typical host factors. It is also like influenza-associated pulmonary aspergillosis but differs in clinical characteristics. For research and clinical practice, the European Confederation for Medical Mycology and the International Society for Human and Animal Mycology proposed novel case definition criteria for CAPA. Although CAPA management is not much different from typical IPA, areas of uncertainty remain that require further investigation.

Abstract

As the coronavirus disease 2019 (COVID-19) pandemic continues, a new disease, COVID-19-associated pulmonary aspergillosis (CAPA), is on the rise. CAPA is a secondary fungal infection in patients with critical COVID-19 receiving mechanical ventilation in intensive care units (ICUs). Although the incidence rate of CAPA is estimated to be 10.2% in ICU patients, CAPA appears to be associated with an increase in overall mortality. CAPA is like classical invasive pulmonary aspergillosis (IPA) but has an ambiguous clinical manifestation and occurs without typical host factors. It is also like influenza-associated pulmonary aspergillosis but differs in clinical characteristics. For research and clinical practice, the European Confederation for Medical Mycology and the International Society for Human and Animal Mycology proposed novel case definition criteria for CAPA. Although CAPA management is not much different from typical IPA, areas of uncertainty remain that require further investigation.

참고문헌 (37)

  1. Wu Z, "Characteristics of and important lessons from the coronavirus disease 2019(COVID-19)outbreak in China : summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention", JAMA, 323, pp.1239~1242 (2020)
  2. COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators, "Clinical characteristics and day-90 outcomes of 4,244 critically ill adults with COVID-19: a prospective cohort study", Intensive Care Med, 47, pp.60~73 (2021)
  3. Musuuza JS, "Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens : a systematic review and meta-analysis", PLoS One, 16, pp.e0251170~ (2021)
  4. Verweij PE, "Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition : an expert opinion", Intensive Care Med, 46, pp.1524~1535 (2020)
  5. 서현민, "COVID-19-associated Pulmonary Aspergillosis: A New Entity", 대한의진균학회지, 26(2), pp.23~27 (2021), 대한의진균학회
  6. Bartoletti M, "Epidemiology of invasive pulmonary aspergillosis among intubated patients with COVID-19 : a prospective study", Clin Infect Dis, 73, pp.e3606~e3614 (2021)
  7. Dellière S, "Risk factors associated with COVID-19-associated pulmonary aspergillosis in ICU patients : a French multicentric retrospective cohort", Clin Microbiol Infect, 27, pp.790.e1~790.e5 (2020)
  8. Permpalung N, "Coronavirus disease 2019-associated pulmonary aspergillosis in mechanically ventilated patients", Clin Infect Dis, 74, pp.83~91 (2022)
  9. Koehler P, "Defining and managing COVID-19-associated pulmonary aspergillosis : the 2020 ECMM", ISHAM consensus criteria for research and clinical guidance, 2021, pp.21, e149~e162
  10. Donnelly JP, "Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium", Clin Infect Dis, 71, pp.1367~1376 (2020)
  11. Verweij PE, "Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis", Intensive Care Med, 47, pp.819~834 (2021)
  12. Van de Veerdonk FL, "COVID-19-associated Aspergillus tracheobronchitis: the interplay between viral tropism, host defence, and fungal invasion", Lancet Respir Med, 9, pp.795~802 (2021)
  13. Thompson GR, 3rd, "Aspergillus infections", N Engl J Med, 385, pp.1496~1509 (2021)
  14. Schauwvlieghe AFAD, "Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza : a retrospective cohort study", Lancet Respir Med, 6, pp.782~792 (2018)
  15. Kuba K, "A crucial role of angiotensin converting enzyme 2(ACE2)in SARS coronavirus-induced lung injury", Nat Med, 11, pp.875~879 (2005)
  16. Arastehfar A, "COVID-19 associated pulmonary aspergillosis(CAPA)-from immunology to treatment", J Fungi(Basel), 6, pp.91~ (2020)
  17. Borczuk AC, "COVID-19 pulmonary pathology : a multi-institutional autopsy cohort from Italy and New York City", Mod Pathol, 33, pp.2156~2168 (2020)
  18. Tolle LB, "Danger-associated molecular patterns(DAMPs)in acute lung injury", J Pathol, 229, pp.145~156 (2013)
  19. Dewi IMW, "Neuraminidase and SIGLEC15 modulate the host defense against pulmonary aspergillosis", Cell Rep Med, 2, pp.100289~ (2021)
  20. Mitaka H, "Incidence and mortality of COVID-19-associated pulmonary aspergillosis : a systematic review and meta-analysis", Mycoses, 64, pp.993~1001 (2021)
  21. Blot SI, "A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients", Am J Respir Crit Care Med, 186, pp.56~64 (2012)
  22. Fekkar A, "COVID-19-associated pulmonary aspergillosis(CAPA) : how big a problem is it", Clin Microbiol Infect, 27, pp.1376~1378 (2021)
  23. Prattes J, "Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients-a multinational observational study by the European Confederation of Medical Mycology", Clin Microbiol Infect (2021)[DOI]
  24. Fekkar A, "Occurrence of invasive pulmonary fungal infections in patients with severe COVID-19 admitted to the ICU", Am J Respir Crit Care Med, 203, pp.307~317 (2021)
  25. White PL, "A national strategy to diagnose coronavirus disease 2019-associated invasive fungal disease in the intensive care unit", Clin Infect Dis, 73, pp.e1634~e1644 (2021)
  26. Janssen NAF, "Multinational observational cohort study of COVID-19-associated pulmonary aspergillosis", Emerg Infect Dis, 27, pp.2892~2898 (2021)
  27. Pan Z, "Diagnostic accuracy of a novel lateral-flow device in invasive aspergillosis : a meta-analysis", J Med Microbiol, 64, pp.702~707 (2015)
  28. Van Biesen S, "Detection of invasive pulmonary aspergillosis in COVID-19 with non-directed bronchoalveolar lavage", Am J Respir Crit Care Med, 202, pp.1171~1173 (2020)
  29. Pritchett MA, "Society for advanced bronchoscopy consensus statement and guidelines for bronchoscopy and airway management amid the COVID-19pandemic", J Thorac Dis, 12, pp.1781~1798 (2020)
  30. Lormans P, "COVID-19 acquisition risk among ICU nursing staff with patient-driven use of aerosol-generating respiratory procedures and optimal use of personal protective equipment", Intensive Crit Care Nurs, 63, pp.102993~ (2021)
  31. Herbrecht R, "Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis", N Eng J Med, 347, pp.408~415 (2002)
  32. Maertens JA, "Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial", Lancet, 387, pp.760~769 (2016)
  33. Park WB, "The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections : a randomized controlled trial", Clin Infect Dis, 55, pp.1080~1087 (2012)
  34. Maertens JA, "Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial", Lancet, 397, pp.499~509 (2021)
  35. Boots RJ, "Successful treatment of post-influenza pseudomembranous necrotising bronchial aspergillosis with liposomal amphotericin, inhaled amphotericin B, gamma interferon and GM-CSF", Thorax, 54, pp.1047~1049 (1999)
  36. Hatzl S, "Antifungal prophylaxis for prevention of COVID-19-associated pulmonary aspergillosis in critically ill patients : an observational study", Crit Care, 25, pp.335~ (2021)
  37. Van Ackerbroeck S, "Inhaled liposomal amphotericin-B as a prophylactic treatment for COVID-19-associated pulmonary aspergillosis", Aspergillus tracheobronchitis, 2021, pp.25, 298~

관련 논문AI추천

COVID-19-associated Pulmonary Aspergillosis: A New Entity김정수, 박세광, 박지훈, 서현민, 오세욱대한의진균학회 · 대한의진균학회지2021 · 제26권 제2호Clinical Characteristics of Patients with Probable Coronavirus Disease 2019-associated Pulmonary Aspergillosis at a Tertiary Care Hospital in the Republic of Korea: A Case Series강창경, 김남중, 김동환, 박완범, 오명돈, 최평균, 황영훈대한의진균학회 · 대한의진균학회지2022 · 제27권 제4호Risk factors and clinical impact of COVID-19- associated pulmonary aspergillosis: multicenter retrospective cohort study이동건, 최정현, Hyeah Choi, Hyojin Ahn, Hyo-Jin Lee, Jae-Ki Choi, Raeseok Lee, Shin Young Kim, Su-Mi Choi, Sung-Yeon Cho, Youn Jeong Kim대한내과학회 · The Korean Journal of Internal Medicine2022 · 제37권 제4호A fatal case report of invasive pulmonary aspergillosis and mucormycosis coinfection in an immunocompetent patient with coronavirus disease 2019 in Korea강병주, 김미성, 김진형, 박선영, 이태훈, 제갈양진, Lim Soyeoun대한중환자의학회 · Acute and Critical Care2023 · 제38권 제3호Epidemiology, the Impact of COVID-19, and the Mycological Approach in Invasive Mold Infection김자영, 성기호, 이혜영대한의진균학회 · 대한의진균학회지2024 · 제29권 제2호Call for evidence mapping in accordance with the changing features of invasive pulmonary aspergillosis during the coronavirus disease 2019 pandemicYoung Kyung Yoon대한내과학회 · The Korean Journal of Internal Medicine2022 · 제37권 제4호

이 간행물의 다른 논문 (5건)

Mycobiome and Microbiome in Seborrheic Dermatitis이동헌, 정혜정pp. 9-13A Case of Superficial Fungal Infection caused by Naganishia diffluens박준수, 최종수, 김택운, 최용우pp. 14-18Pilomatricoma Developed After SARS-CoV-2 mRNA Vaccine Inoculation홍나랑, 정혜정, 박미연, 안지영, 이동헌, 국형돈pp. 19-20Scarring Alopecia After Kerion Celsi in Adults박세광, 박지훈, 김정수, 김기연, 서현민pp. 21-22A Dermoscopic Finding of Tinea Capitis caused by Microsporum canis권형목, 정은혜, 임정은, 최종수pp. 23-24
원문 보기